CBPd-171
FHT-171 Small Molecule Target: CBP
Foghorn Therapeutics
Most recent annual filing: 2026-03-11
- Selective ARID1B degrader readout2026Selective ARID1B degrader readout, 2026, notable
- Selective CBP degrader corporate update2026Selective CBP degrader corporate update, 2026, routine
- Selective EP300 degrader corporate update2026Selective EP300 degrader corporate update, 2026, routine
- Selective EP300 degrader IND filing2027Selective EP300 degrader IND filing, 2027, notable
- Undisclosed I&I small molecule IND2027Undisclosed I&I small molecule IND, 2027, notable
- Company cash runway guidance update1H 2028Company cash runway guidance update, 1H 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Technology platforms
Gene Traffic Control · Eli Lilly and Company
Proprietary platform providing integrated and mechanistic understanding of the chromatin regulatory system; used to identify, validate and drug targets within this system; focus areas include oncology and immunology/inflammation. Enables discovery of small molecules including protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors targeting SMARCA2 (BRM), CBP, EP300, ARID1B and other undisclosed targets.
Targets: SMARCA2, CBP, EP300, ARID1B, BRM
Gene Traffic Control Platform · Eli Lilly
Chromatin biology-based drug discovery platform leveraging deep mechanistic understanding of chromatin regulatory system to identify and develop selective small molecules and degraders targeting chromatin remodeling complexes, transcription factors, and other chromatin binding proteins; focus areas include oncology and immunology/inflammation
Targets: SMARCA2, ARID1B, CBP, EP300
Gene Traffic Control · Lilly
Chromatin regulatory system platform for systematically studying, identifying, and validating drug targets within chromatin biology; focus areas include oncology and immunology & inflammation; enables discovery of inhibitors, degraders, molecular glues, RIPTACs, and induced proximity molecules
Targets: SMARCA2, SMARCA4, EP300, CBP, ARID1B
Gene Traffic Control
Proprietary scalable platform for systematically studying, identifying, and validating drug targets within the chromatin regulatory system; disease focus: oncology and immunology & inflammation
Discontinued (1)
- FHD-909 — Non-Small Cell Lung Cancer · SMARCA2/4 synthetic lethality biology did not translate into sufficient efficacy in Phase 1
Biotech Distilled coverage (3)
- 2026-10-02 UPDATE: Foghorn Therapeutics (FHTX) - Lilly Opened the Envelope 🔒 Paid
- 2026-08-07 UPDATE: Foghorn Therapeutics (FHTX) - The CRO Ate Their Homework 🔒 Paid
- 2026-07-08 Foghorn Therapeutics (FHTX) — Scientific Deep Dive for FHD-909 and the Chromatin Degrader Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.